A Note from the President
TransPharm has given me some wonderful opportunities over the last 4 years. Locally, we volunteer for Junior Achievement, Big Brothers/Big Sisters, and donate to numerous charities that I wouldn’t have been able to in the past.
At the state level, we were recognized as one of the Top 50 Companies to Watch in Michigan in 2011. I was invited to a business round table discussion and met with Jennifer Granholm, Michigan’s outgoing Governor. I was also invited to Governor Rick Snyder’s residence in Lansing for the Moores River Drive Breakfast. Both events brought together many of the state’s business leaders and gave us a chance to meet with some of our state representatives to hear some of the new initiatives that are in the works for small business owners.
At the national level, TransPharm has traveled to both the East and West Coasts and many cities in between to attend the annual ICAAC conference. This year’s event is being held in San Francisco, California. Please stop by booth 1014 and say hello.
I feel extremely lucky to have traveled to London, England to attend the European Congress of Clinical Microbiology and Infectious Diseases. The conference boasted attendance from 106 different countries. It was my first trip to Europe and I can’t overstate how wonderful it was. Ironically, I met a family in our hotel that lives about 25 miles from me in Michigan. It just goes to show how small this world is these days. I’m already looking forward to attending the conference next year in Berlin, Germany.
President and CEO
TransPharm’s Development Incubator
To update you on our current model development here at TransPharm, I’d like to announce that our first viral sepsis model, Herpes Simplex Virus 1, is just about completed! Once the finishing touches are added within the next few days we’ll be ready to roll this out to all our interested clients (Figure 1). Also while the viral models are emerging from our development incubator, we’ve also established a neonatal rat sepsis model using Staphylococcus epidermidis (Figure 2). This model mimics the clinical manifestation sometimes seen in low birth weight human infections.
In recent months, a new, advantageous partnership has emerged between TransPharm and HuMurine Technologies (www.humurine.com). Using their proprietary Hu-M™ CIEA NOG mouse® model as a background, HuMurine has developed a commercialized humanized mouse, named the Hu-M™ ID Model, to study infectious disease. With their novel humanized mouse model and TransPharm’s preclinical testing experience, this joint venture has the potential to greatly benefit institutions that desire to test compound efficacy in a preclinical, human immunological environment. We are looking to develop a hu-mouse model for all current TransPharm pathogens, as well as new ones such as Malaria and Dengue. Stay tuned for updates on this exiting, new partnership!
Dr. Santiago R. Lopez
Director of Research
Dan Hits the Airwaves!
Dan Ross, President & CEO of TransPharm, was recently interviewed by the Michigan Business Network. Click the link below to listen to the podcast.
A Note From The President
Let me be the last person to wish you a Happy New Year! 2011 proved to be a year full of challenges and rewards for us here at TransPharm. We have had many requests to run in vivo models of pathogens we have not yet validated. While it’s nearly impossible to have data in hand for all the possible requests we could receive, we are now fully committed to putting more resources into project validations. TransPharm has many new models that we plan to roll out in 2012 and Dr. Lopez will touch on a few of those below. Marci Peek, our Contract & Protocol Specialist, will also inform you of some news regarding our product, the Final Report.
We closed the year with a 15% increase in revenue over 2010, making it our best year to date. This is one reason TransPharm will be making new commitments to our clients in 2012. Our pricing structure will remain untouched, new models will be rolled out, and we are instating a new Final Report Guarantee. These are just a few ways we are saying thank you for your business.
President and CEO
TransPharm is Going Viral!
The year 2012 promises many exciting projects for the Research and Development team here at TransPharm! One of these projects involves expanding our current models of infection to include viral models, namely Herpes Simplex Virus (HSV) types 1 and 2. With the various clinical manifestations of this pathogen and its prevalence worldwide, we believe HSV is a logical entry point into the viral infection modeling realm. TransPharm is currently in the process of developing and validating both an in vitro model to detect early viral mRNA transcripts as well as an in vivo sepsis model of HSV infection. We have also laid the groundwork to explore the murine model of latency and reactivation of all herpes viruses.
Another area of research we are excited about is the development of a mouse model for malaria infections (Plasmodium falciparum). As the world’s second biggest killer (just behind tuberculosis) and with relatively little research going into anti-malaria medications, TransPharm believes this model will aid in the search for cost-effective treatments for this deadly disease. So stay tuned for updates regarding TransPharm’s upcoming infection models!
Please contact me directly if you have any questions or specific needs related to these models.
Dr. Santiago R. Lopez
Director of Research
“Final Report Guarantee”
Historically, TransPharm has aimed for a turn-around time of approximately 2 months from study end to delivery of the final report to the client. Unfortunately, this timeline was not always able to be met. In 2012, however, we are confident that we will be able to consistently meet an even tighter timeline of 1 month or less between study end and final report delivery. We have made some changes internally and fully expect to fulfill this goal. If for any reason we fail to meet this timeline, we will deduct $200 from the final payment.
And as always, clients will receive their raw data package within 1 week of study completion, in the form of an Excel spreadsheet with data analyses included.
Contracts and Protocol Specialist